Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What Each Is
Fisetin
Dietary SupplementFisetin is a dietary flavonoid studied primarily as a senolytic agent. Found in strawberries. Early-stage human evidence. Poor oral bioavailability (<10%). Not FDA GRAS.
Urolithin A
Dietary SupplementUrolithin A is a postbiotic produced by gut bacteria from dietary ellagitannins (found in pomegranates, berries, nuts). It activates mitophagy — the selective recycling of damaged mitochondria. Has received FDA GRAS status (specific manufacturer). Multiple published human trials demonstrating safety and functional outcomes.
Evidence Type Comparison
Understanding the difference in evidence quality between these options.
| Aspect | Fisetin | Urolithin A |
|---|---|---|
| FDA Status | Not FDA-approved for any condition | Not FDA-approved; FDA GRAS status obtained |
| Primary Mechanism | Senolytic (BCL-xL inhibition, cell clearance) | Mitophagy activation (mitochondrial recycling) |
| Human Evidence Stage | Early-stage safety/tolerability | Functional outcome RCTs (muscle, mitochondrial biomarkers) |
| Oral Bioavailability | <10% (very poor) | Better characterized; generally superior |
| Dosing Approach | Intermittent (2 days/month) | Daily (500–1000 mg/day) |
| Safety Data Maturity | Limited (<500 participants) | Multiple published human trials up to 4 months |
Mechanism Hypotheses (Conceptual)
Note: Mechanism hypotheses describe how compounds are thought to work based on laboratory research. This does not confirm clinical benefit or efficacy in humans.
Fisetin
Targets cellular senescence by inhibiting BCL-xL anti-apoptotic proteins in senescent cells. This is a 'clearance' approach — removing damaged cells. Uses intermittent dosing (2 days on, 28 days off) based on the hypothesis that brief exposure triggers senescent cell apoptosis.
Urolithin A
Activates mitophagy — the selective recycling of damaged mitochondria. This is a 'repair' approach — improving existing cellular function rather than eliminating cells. Produced naturally by gut bacteria from dietary ellagitannins (pomegranates, berries), though production varies widely between individuals.
Critical difference: These are complementary rather than competing mechanisms. Some researchers have theorized that combining senolytic and mitophagy-activating approaches could provide broader anti-aging benefits, but this combination has not been studied.
Safety & Tolerability Patterns
Fisetin
Limited human safety data (<500 participants total). Well-tolerated at 20 mg/kg/day for 2-day courses. No FDA GRAS status. Comprehensive drug interaction studies lacking.
Urolithin A
Substantially more human safety data. FDA GRAS status obtained (specific manufacturer). Multiple published human trials demonstrating safety at 500–1000 mg/day for up to 4 months. Better-characterized pharmacokinetics.
Key difference: Urolithin A has a significantly more mature safety and evidence profile than fisetin. This does not mean Urolithin A is proven 'effective' for anti-aging, but its safety characterization is more advanced.
Drug Interaction Considerations
Fisetin may affect CYP3A4 drug-metabolizing enzymes; Urolithin A's drug interaction profile is less studied despite its GRAS status. Both warrant caution with prescription medications.
Always discuss any supplements with your pharmacist, especially if you take prescription medications.
Decision Factors to Discuss Clinically
These factors should be discussed with your healthcare provider—not decided based on online information alone:
- •Current medications and potential interactions
- •Other health conditions (comorbidities)
- •Symptom severity and impact on quality of life
- •Your goals and preferences for treatment approach
- •How you'll objectively track symptom changes
Questions to Bring to Your Appointment
Discussing supplements with your healthcare provider
Between these supplements, which has the most evidence for my goals?
Comparing options based on published clinical evidence
Could combining supplements increase side effect risk?
Understanding multi-ingredient formulas and interactions
How do I choose a quality supplement product?
Third-party testing, standardization, reputable brands
What's a reasonable trial period before deciding if a supplement works?
Timeline for evaluation
At what point should I consider prescription options instead?
Knowing when supplements aren't enough
Tip: Write down these questions before your appointment. Bring a list of all current medications and supplements you take, including dosages. Consider asking about objective symptom tracking to measure changes over time.
Quick Answers
Is fisetin or Urolithin A better?
They work by different mechanisms (fisetin clears senescent cells; Urolithin A recycles mitochondria). Neither is proven 'better' for anti-aging. Urolithin A has more mature human evidence; fisetin has stronger preclinical senolytic data.
What is the main difference?
Fisetin is a senolytic (clears damaged 'zombie' cells via BCL-xL inhibition). Urolithin A is a mitophagy activator (recycles damaged mitochondria). Fisetin = clearance; Urolithin A = repair.
Which has more human evidence?
Urolithin A has substantially more published human clinical data, including multiple RCTs with functional outcomes (muscle, mitochondrial biomarkers). Fisetin's human evidence is primarily safety/tolerability.
Can I take both fisetin and Urolithin A?
Combining them has not been studied. They are mechanistically complementary (senolytic + mitophagy), but there's no safety or efficacy data on the combination. Consult a healthcare provider.
Which has FDA GRAS status?
Urolithin A (Mitopure®) has received FDA GRAS status. Fisetin has not.
Where does each come from?
Fisetin comes from strawberries and other plants. Urolithin A is produced by gut bacteria from ellagitannins in pomegranates, berries, and nuts — though production varies widely between individuals.
Which is better absorbed?
Urolithin A bioavailability is better characterized and generally superior to fisetin's estimated <10% oral bioavailability.
Do they work on the same cells?
No. Fisetin targets senescent cells (clearance). Urolithin A targets damaged mitochondria within cells (repair/recycling). They address different hallmarks of aging.
Which is better for muscle health?
Urolithin A has published human trials showing improved muscle biomarkers and mitochondrial function. Fisetin has no human muscle data.
Are they both natural?
Fisetin is a plant flavonoid. Urolithin A is a postbiotic produced by gut bacteria from dietary ellagitannins — but only in individuals with the right gut microbiome.
Which dosing protocol is easier?
Urolithin A is daily (500–1000 mg/day). Fisetin uses intermittent high-dose pulses (2 days/month). Both are feasible; daily dosing may be easier to remember.
Which is more expensive?
Urolithin A (especially Mitopure®) tends to be more expensive due to proprietary production. Fisetin supplements vary in price.
Could combining them be the best approach?
Combining senolytic (fisetin) and mitophagy (Urolithin A) approaches is theoretically attractive but has no supporting clinical evidence.
Which has better-quality supplements available?
Urolithin A has a branded, clinically-tested form (Mitopure®). Fisetin supplement quality varies widely with little third-party validation.
What does the research community prioritize?
Both are active areas of aging research. Urolithin A has progressed to functional outcome trials; fisetin is still primarily in safety/tolerability studies.
Key Research Facts
Fisetin targets cellular senescence (clearing damaged cells) while Urolithin A activates mitophagy (recycling damaged mitochondria) — fundamentally different mechanisms.
Strong EvidenceMechanism comparison — Yousefzadeh et al., 2018 + Andreux et al., 2019
Urolithin A has substantially more published human clinical data than fisetin, including multiple RCTs with functional outcomes.
Strong EvidenceLiterature comparison — PubMed search
Urolithin A (Mitopure®) has received FDA GRAS status; fisetin has not.
Strong EvidenceFDA regulatory records — GRAS Notices
Fisetin uses intermittent dosing (2 days/month) while Urolithin A uses daily dosing (500–1000 mg/day) — reflecting different biological rationales.
Strong EvidenceClinical trial protocols — Protocol comparison
Urolithin A has demonstrated measurable mitophagy activation and improved muscle biomarkers in published human trials.
Strong EvidenceAndreux et al., Nature Metabolism — doi:10.1038/s42255-019-0073-4
Fisetin's human evidence is primarily safety/tolerability data, while Urolithin A has progressed to functional outcome measurements.
Strong EvidenceLiterature comparison — Evidence stage assessment
No published study has examined the combination of fisetin and Urolithin A for safety or efficacy.
Strong EvidenceLiterature review — PubMed search, 2026
Urolithin A bioavailability is better characterized and generally superior to fisetin's estimated <10% oral bioavailability.
Moderate EvidencePK comparison — Grynkiewicz & Demchuk, 2019 + Andreux et al., 2019
Both compounds are marketed as 'anti-aging' supplements, but marketing claims frequently exceed what published evidence supports for either.
Strong EvidenceMarket analysis — Evidence review
Combining senolytic (fisetin) and mitophagy (Urolithin A) approaches is theoretically attractive but has no supporting clinical evidence.
Emerging EvidenceTheoretical analysis — Hypothesis only
Continue Your Research
Explore related topics and take the next step in your cellular health journey.
Related Comparisons
Explore more head-to-head supplement comparisons backed by clinical evidence.
CoQ10 vs PQQ: Which Mitochondrial Supplement Has Better Evidence?
CoQ10 and PQQ are both positioned as mitochondrial supplements, but they work through fundamentally different mechanisms. CoQ10 supports existing mitochondria; PQQ stimulates creation of new ones.
Creatine vs CoQ10: Cellular Energy Supplements Compared
Creatine and CoQ10 both support cellular energy but through entirely different mechanisms. Creatine rapidly regenerates ATP; CoQ10 supports steady-state mitochondrial ATP production.
NMN vs NR: Comparing NAD+ Precursors — Evidence & Differences
NMN and NR are the two leading NAD+ precursors. Both increase cellular NAD+, but differ in metabolic pathways, clinical evidence base, regulatory status, and availability.
Glutathione vs NAC: Direct Supplementation vs Precursor Strategy
Glutathione and NAC represent two strategies for supporting the master antioxidant system: direct supplementation vs. precursor strategy. Each has distinct advantages and evidence.
Curcumin vs Omega-3: Anti-Inflammatory Supplements Compared
Curcumin and omega-3 are the two most popular anti-inflammatory supplements. Omega-3s have strong clinical evidence; curcumin's translation from lab to clinic remains challenging.
Magnesium Forms Compared: Glycinate vs Threonate vs Citrate vs Oxide
Magnesium supplements come in many forms with different bioavailability and clinical applications. Choosing the right form depends on your specific health goals.
Citations & External Resources
ClinicalTrials.gov — Search: Fisetin
PubMed — Fisetin research
EBioMedicine — Yousefzadeh et al. 2018
Nature Metabolism — Andreux et al. 2019 (Urolithin A Human Trial)
J Internal Medicine — Kirkland & Tchkonia 2020 (Senolytic Context)
Related Reading
Fisetin: The Complete Evidence-Based Guide
Urolithin A: Mitophagy & Cellular Renewal
How Fisetin Works: Senolytic Mechanisms
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026